Binnopharm Group’s ARMAN trial results to be presented at the VI European Congress on Infectious Diseases, Amsterdam
09.09.2024
The results of Kagocel (managed by Binnopharm Group) open-label, multi-centre, observational non-interventional ARMAN 2024 trial, which covered six clinical centres in Kazakhstan and included 1000 ARVI patients, will be reported at the VI European Congress on Infectious Diseases, which will be held on October 3-4, 2024 at Amsterdam, the Netherlands.
The study was aimed to assess the dynamics of quality of life and adherence to treatment when Kagocel was prescribed within 24 to 72 hours of the onset of mild to moderate symptoms. The ARMAN results demonstrated the interferon defence system being a comprehensive drug therapy for the treatment of acute respiratory viral infections and influenza in a broad patient population, which is particularly relevant for the routine clinical practice settings where pathogen identification is not possible.
Natalia Oliferuk, Head of Medical Department, Binnopharm Group: «The level of post-marketing studies of our portfolio drugs allows us to participate actively in the most renowned international congresses. Recently, the results of our Urdoxa studies were accepted to be reported at the UEG Week 2024, which will be hosted in Vienna. Binnopharm Group is increasing its presence at global industry events. The international expansion strategy implies active work on the company’s brands recognition among foreign specialists and confirming its reputation as a world-class drug manufacturer».
The European Congress on Infectious Diseases conference brings together scientists, researchers and drug industry professionals from all over the world at one platform, includes a series of B2B and B2C meetings, presentations, workshops, and exhibitions. This year theme is «Defeating the Invisible Foe: Advancing Infectious Disease Control and Research».
The study was aimed to assess the dynamics of quality of life and adherence to treatment when Kagocel was prescribed within 24 to 72 hours of the onset of mild to moderate symptoms. The ARMAN results demonstrated the interferon defence system being a comprehensive drug therapy for the treatment of acute respiratory viral infections and influenza in a broad patient population, which is particularly relevant for the routine clinical practice settings where pathogen identification is not possible.
Natalia Oliferuk, Head of Medical Department, Binnopharm Group: «The level of post-marketing studies of our portfolio drugs allows us to participate actively in the most renowned international congresses. Recently, the results of our Urdoxa studies were accepted to be reported at the UEG Week 2024, which will be hosted in Vienna. Binnopharm Group is increasing its presence at global industry events. The international expansion strategy implies active work on the company’s brands recognition among foreign specialists and confirming its reputation as a world-class drug manufacturer».
The European Congress on Infectious Diseases conference brings together scientists, researchers and drug industry professionals from all over the world at one platform, includes a series of B2B and B2C meetings, presentations, workshops, and exhibitions. This year theme is «Defeating the Invisible Foe: Advancing Infectious Disease Control and Research».
